Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab.

Vedolizumab, a monoclonal antibody targeting αβ leukocyte integrins, has demonstrated efficacy for induction and maintenance of remission in ulcerative colitis (UC). However, it remains unclear whether oral aminosalicylates should be continued or stopped after treatment escalation to vedolizumab. Singh et al have demonstrated no significant difference in clinical remission, clinical response, or mucosal healing rates between patients treated with or without concomitant aminosalicylates at entry in clinical trials of infliximab or golimumab. We evaluate the impact of concomitant oral aminosalicylates on clinical outcomes for vedolizumab-treated UC patients.